Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,630 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07492394RecruitingPhase 2
Testing dalpiciclib with or without entinostat and letrozole for early breast cancer
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
Shijiazhuang, HebeiAges 18–75 - NCT07493421Recruiting
Surgery and heated chemotherapy for pancreatic cancer with spread to the abdomen
This trial tests if combining surgery to remove the tumor with a special heated chemotherapy bath for the abdomen (HIPEC) is safe and possible for people whose pancreatic cancer has spread only to the lining of the abdomen.
Shanghai, shangaiShanghai MunicipalityAges 18 years+ - NCT07495384Recruiting
CapsuleX and cisplatin for platinum-resistant ovarian cancer
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Changchun, JilinAges 18 years+ - NCT07495397Recruiting
Daphnetin plus chemo for advanced ovarian cancer maintenance
This trial is testing a combination of two drugs—daphnetin capsules and a standard chemotherapy (TC regimen)—as a targeted maintenance therapy after initial surgery for advanced ovarian cancer. The goal is to see if this treatment can help keep the cancer from coming back.
Changchun, JilinAges 18–75 - NCT07498478RecruitingPhase 2
Tinengotinib and fulvestrant for advanced HR+ HER2- breast cancer
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07500012Recruiting
Ear nerve stimulation for breast cancer pain
This study tests whether gentle electrical stimulation of a nerve in your ear (called taVNS) can help reduce pain and improve symptoms for breast cancer survivors. You would need to have finished your main treatments, have ongoing pain, and be willing to provide stool samples and undergo brain scans.
Tallahassee, FloridaAges 18–79 - NCT07503756RecruitingPhase 2
JS212 Combination for Untreated Metastatic Colorectal Cancer
This trial tests a new drug called JS212 in combination with other medicines for people with metastatic colorectal cancer that has not been treated before. It focuses on patients whose tumors are MSS or pMMR and aims to see if these combinations are safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07504471RecruitingPhase 2
Bicarbonate plus chemo and immunotherapy for pancreatic cancer liver spread
This trial tests adding sodium bicarbonate to a chemotherapy plus immunotherapy regimen for pancreatic cancer that has spread to the liver. The goal is to see if this combination helps shrink tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07504523RecruitingPhase 1
Personalized T-cell therapy for advanced colorectal cancer
This trial tests a custom-made T-cell treatment designed to target unique markers on your tumor. It's for people with advanced colorectal cancer who have run out of standard options or can't take them, and it aims to shrink tumors and improve survival.
Hangzhou, ZhejiangAges 18–70 - NCT07504835Recruiting
Exercise program for older men with prostate cancer
This study tests whether a special exercise program done with other men (via video calls) can help older men with prostate cancer feel less lonely. You'd be placed in one of three groups and attend regular exercise sessions from home.
Portland, OregonAges 65 years+ - NCT07505472RecruitingPhase 2/Phase 3
Short radiation plus chemo and immunotherapy for high-risk rectal cancer
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Changchun, JilinAges 18–75 - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT07512154Recruiting
Precision Brain Tumor Radiotherapy Using Advanced MRI
This study tests a new way to plan and deliver radiation therapy for glioblastoma (an aggressive brain tumor) using special MRI scans to target cancer cells more precisely. The goal is to improve treatment effectiveness while reducing harm to healthy brain tissue.
Baltimore, MarylandAges 18 years+ - NCT07518147RecruitingPhase 3
BL-M05D1 for advanced stomach cancer after first treatment
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07519837Recruiting
Understanding Cancer Wasting in Digestive Cancers
This study explores why certain cancers cause patients to lose weight and muscle (called cancer cachexia) and tests ways to reverse it. Researchers will study tissue samples from patients with cancers of the food pipe, liver, stomach, or bile ducts to understand what's happening at a cellular level.
Shenyang, LiaoningAges 18 years+ - NCT07520760RecruitingPhase 2
Eribulin Plus Anlotinib for HER2-Negative Breast Cancer
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
GuangzhouAges 18 years+ - NCT07524426Recruiting
Local Radiation Therapy for Bladder Cancer Not Suitable for Surgery
This trial tests whether focused radiation therapy directed at the bladder can help patients with muscle-invasive bladder cancer who are not candidates for surgical removal or have chosen not to have surgery. The goal is to see if this approach can control the cancer and improve quality of life.
Umeå, Västerbotten CountyAges 18 years+ - NCT07524829Recruiting
Phone-based nurse support for breast cancer medication side effects
This study tests whether regular phone check-ins with a nurse can help catch and manage side effects from CDK4/6 inhibitor medications (like palbociclib, ribociclib, or abemaciclib) that you're taking for breast cancer. The goal is to help you stay on treatment safely and feel better.
Asti, ASTIAges 18 years+ - NCT07525869Recruiting
Pegfilgrastim to prevent low white blood cells in triple-negative breast cancer
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
Seoul, Seodaemun-guAges 19–70 - NCT07529717RecruitingPhase 1/Phase 2
Early-stage study of AZD8359 for advanced prostate cancer
This study tests a new experimental drug (AZD8359) designed to target prostate cancer cells in men whose cancer has progressed despite previous treatments. The drug works by directing immune cells to attack cancer cells.
Orlando, FloridaAges 18–100 - NCT07530445RecruitingPhase 2
Immunotherapy plus chemotherapy for advanced biliary tract cancer
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted drug (lenvatinib) for biliary tract cancer that has spread or cannot be surgically removed. The goal is to slow cancer growth in patients whose cancer has progressed after one prior treatment.
GuangzhouAges 18–70 - NCT07533123RecruitingPhase 3
New drug JSKN016 for triple-negative breast cancer after chemotherapy
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
Guangzhou, GuangdongAges 18–75 - NCT07535541Recruiting
Smartwatch Study of Hot Flashes in Prostate Cancer Patients
This study tests whether a smartwatch can accurately measure hot flashes (sudden heat and sweating) that occur in men undergoing hormone therapy for prostate cancer. You'll wear the smartwatch for about 4 weeks while the research team tracks your symptoms.
Charlottesville, VirginiaAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,630 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.